Ferrosan Medical Devices Group A/S - Group

 

Quicksearch
from your own companies




Analyst: XBRLDenmarkIFRS
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.5% 1.0% 0.5% 0.5% 0.5%  
Credit score (0-100)  78 87 99 99 99  
Credit rating  A A AAA AAA AAA  
Credit limit (mDKK)  2.2 23.1 62.5 75.0 83.7  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  530 528 622 720 810  
Gross profit  340 335 487 563 605  
EBITDA  103 121 225 286 322  
EBIT  -8.3 18.7 127 187 213  
Pre-tax profit (PTP)  -6.1 22.9 67.8 135.5 164.3  
Net earnings  -6.1 22.9 50.8 102.9 136.9  
Pre-tax profit without non-rec. items  -6.1 22.9 67.8 135 164  

 
See the entire income statement

Balance sheet (mDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  90.1 101 117 306 325  
Shareholders equity total  592 335 469 562 620  
Interest-bearing liabilities  0.0 0.0 94.2 935 899  
Balance sheet total (assets)  1,850 1,757 1,943 1,974 2,016  

Net Debt  -49.7 -16.2 77.0 935 883  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  530 528 622 720 810  
Net sales growth  9.0% -0.4% 17.9% 15.7% 12.5%  
Gross profit  340 335 487 563 605  
Gross profit growth  19.9% -1.3% 45.1% 15.6% 7.6%  
Employees  269 287 0 345 360  
Employee growth %  6.3% 6.7% -100.0% 0.0% 4.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,850 1,757 1,943 1,974 2,016  
Balance sheet change%  -3.0% -5.0% 10.6% 1.6% 2.2%  
Added value  102.9 121.2 225.2 284.9 321.6  
Added value %  19.4% 23.0% 36.2% 39.6% 39.7%  
Investments  -96 -92 -66 114 -48  

Net sales trend  2.0 -1.0 1.0 2.0 3.0  
EBIT trend  -1.0 1.0 2.0 3.0 4.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  19.4% 23.0% 36.2% 39.8% 39.7%  
EBIT %  -1.6% 3.5% 20.4% 25.9% 26.3%  
EBIT to gross profit (%)  -2.4% 5.6% 26.1% 33.2% 35.3%  
Net Earnings %  -1.2% 4.3% 8.2% 14.3% 16.9%  
Profit before depreciation and extraordinary items %  19.8% 23.8% 24.0% 28.2% 30.2%  
Pre tax profit less extraordinaries %  -1.2% 4.3% 10.9% 18.8% 20.3%  
ROA %  -0.3% 1.3% 7.0% 9.6% 11.1%  
ROI %  -0.3% 1.3% 7.7% 11.7% 13.6%  
ROE %  -0.9% 4.9% 12.6% 20.0% 23.2%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  69.9% 58.0% 24.1% 28.5% 30.8%  
Relative indebtedness %  0.0% 0.0% 237.0% 196.0% 172.3%  
Relative net indebtedness %  -9.4% -3.1% 234.2% 196.0% 170.2%  
Net int. bear. debt to EBITDA, %  -48.2% -13.4% 34.2% 326.4% 274.6%  
Gearing %  0.0% 0.0% 20.1% 166.5% 145.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 129.3% 10.3% 6.3%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 0.0 0.5 0.4 0.8  
Current Ratio  0.0 0.0 0.9 0.6 1.3  
Cash and cash equivalent  49.7 16.2 17.2 0.0 16.3  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 53.8 54.4 57.5  
Trade creditors turnover (days)  0.0 0.0 265.8 157.2 310.5  
Current assets / Net sales %  37.1% 34.3% 31.5% 28.8% 31.3%  
Net working capital  196.8 180.9 -33.6 -123.2 54.5  
Net working capital %  37.1% 34.3% -5.4% -17.1% 6.7%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  2 2 0 2 2  
Added value / employee  0 0 0 1 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 1 1  
EBIT / employee  -0 0 0 1 1  
Net earnings / employee  -0 0 0 0 0